Blockage of interleukin-1β with canakinumab in patients with Covid-19

There is the urgent need to study the effects of immunomodulating agents as therapy for Covid-19. An observational, cohort, prospective study with 30 days of observation was carried out to assess clinical outcomes in 88 patients hospitalized for Covid-19 pneumonia and treated with canakinumab (300 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Landi, Lorenza, Ravaglia, Claudia, Russo, Emanuele, Cataleta, Pierluigi, Fusari, Maurizio, Boschi, Andrea, Giannarelli, Diana, Facondini, Francesca, Valentini, Ilaria, Panzini, Ilaria, Lazzari-Agli, Luigi, Bassi, Paolo, Marchionni, Elisa, Romagnoli, Rossella, De Giovanni, Raffaella, Assirelli, Marina, Baldazzi, Federica, Pieraccini, Fabio, Rametta, Giovanna, Rossi, Lucia, Santini, Luca, Valenti, Ivana, Cappuzzo, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733468/
https://www.ncbi.nlm.nih.gov/pubmed/33311551
http://dx.doi.org/10.1038/s41598-020-78492-y

Ejemplares similares

Ejemplares similares